GlassScriptPhysician profile
Sanjay Mehra
NPI 1629136205
$4,499.82
in general payments reported to CMS, 2019-2025
26 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $404 · 2021: $760 · 2022: $1,052 · 2023: $491 · 2024: $654 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $634.21 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $567.41 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $507.70 | 2019-2025 | |
| Amgen INC. | $437.79 | 2019-2025 | Repatha, Repatha |
| Vital Connect, INC | $432.30 | 2022-2023 | Vitalpatch Rtm |
| Merck Sharp & Dohme LLC | $296.29 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $252.17 | 2019-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.99 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $147.01 | 2021-2025 | Farxiga |
| Cvrx, INC. | $128.78 | 2022-2024 | Barostim Neo System |
| Corvista Health, INC. | $114.85 | 2025 | Corvista System |
| Irhythm Technologies, INC. | $110.76 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $89.55 | 2022-2023 | |
| Novo Nordisk INC | $87.34 | 2021-2025 | Wegovy, Ozempic |
| Regeneron Healthcare Solutions, INC. | $81.67 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $62.86 | 2021-2022 | |
| Esperion Therapeutics, INC. | $62.00 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $48.54 | 2025 | |
| Abbott Laboratories | $46.06 | 2022 | |
| Glaxosmithkline, LLC. | $43.55 | 2023 | Trelegy Ellipta |
| Philips North America LLC | $34.34 | 2022 | |
| Arbor Pharmaceuticals, INC. | $26.21 | 2019 | |
| Medtronic, INC. | $22.77 | 2025 | Mycarelink |
| Genzyme Corporation | $22.17 | 2024 | |
| Corcept Therapeutics | $19.32 | 2025 | Korlym |
| Amarin Pharma, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,807.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.